C4710
Monoclonal Anti-Cyclin A antibody produced in mouse
clone CY-A1, ascites fluid
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Acerca de este artículo
Conjugate:
unconjugated
Clone:
CY-A1, monoclonal
Application:
ARR, ICC, WB
Citations:
48
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleServicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlebiological source
mouse
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
CY-A1, monoclonal
mol wt
antigen 60 kDa
contains
15 mM sodium azide
species reactivity
mouse, human, monkey, bovine
technique(s)
immunocytochemistry: suitable, microarray: suitable, western blot: 1:1,000 using a mouse NIH 3T3 cell extract
isotype
IgG2a
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... CCNA2(890)
mouse ... Ccna2(12428)
General description
Cyclin A is a nuclear protein during S phase and it binds both cdk2 and cdc2. The availability of monoclonal antibody reacting specifically with cyclin A enables the subcellular detection and localization of cyclin A and the measurement of relative differences in cyclin A levels as a function of cell cycle phase.
Immunogen
recombinant bovine cyclin A.
Application
Monoclonal Anti-Cyclin A antibody produced in mouse is suitable for:
- immunocytochemistry
- microarray
- western blotting at a dilution of 1:1,000 using a mouse NIH 3T3 cell extract
Biochem/physiol Actions
The antibody recognizes an epitope present in amino acids 162-433 of bovine cyclin A. No cross-reactivity is detected with other cyclins (cyclin B, D, or E).
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Clase de almacenamiento
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Matthew Hoare et al.
Nature cell biology, 18(9), 979-992 (2016-08-16)
Senescence, a persistent form of cell-cycle arrest, is often associated with a diverse secretome, which provides complex functionality for senescent cells within the tissue microenvironment. We show that oncogene-induced senescence is accompanied by a dynamic fluctuation of NOTCH1 activity, which
Qing-Hua Zhang et al.
The Journal of cell biology, 216(10), 3133-3143 (2017-08-19)
Cyclin A2 is a crucial mitotic Cdk regulatory partner that coordinates entry into mitosis and is then destroyed in prometaphase within minutes of nuclear envelope breakdown. The role of cyclin A2 in female meiosis and its dynamics during the transition
Emma L Hesketh et al.
Cell cycle (Georgetown, Tex.), 14(3), 333-341 (2015-02-07)
The minichromosome maintenance complex (MCM2-7) is the putative DNA helicase in eukaryotes, and essential for DNA replication. By applying serial extractions to mammalian cells synchronized by release from quiescence, we reveal dynamic changes to the sub-nuclear compartmentalization of MCM2 as
J E Dazard et al.
Oncogene, 19(33), 3693-3705 (2000-08-19)
p53 transcription factor is mutated in most skin cell carcinomas and in more than 50% of all human malignancies. One of its transcriptional targets is MDM2, which in turn down-regulates p53. The role of the p53/MDM2 regulatory loop upon genotoxic
Chunyan Weng et al.
International journal of oncology, 42(1), 327-337 (2012-11-09)
Androgen deprivation therapy of prostate cancer with estrogens shows significant cardiovascular side-effects. To develop effective prostate cancer therapeutic agent(s) with minimal cardiovascular side-effects, we compared the effects of various estrogen receptor (ER) ligands on the modulation of dihydrotestosterone (DHT) actions
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico